New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment

Future Oncology

Volumn 8, Issue 5, 2012, Pages 559-573

  Gori, Bruno ^a   Ricciardi, Serena ^a   Fulvi, Alberto ^a   Del Signore, Ester ^a   De Marinis, Filippo ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

angiogenesis; antiangiogenic therapy; biomarker; non small cell lung cancer; oral tyrosine kinase inhibitor; targeted agent

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; DOCETAXEL; ERLOTINIB; GROWTH FACTOR; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANGIOGENESIS; ANOREXIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL (TOPIC); DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PROGNOSIS; PROTEIN KINASE INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861738322     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.48     Document Type: Review

References (77)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 407, 249-257 (2000).
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 235, 442-447 (1987). (Pubitemid 17009577)
3. Keedy VL, Sandler AB. Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Sci. 98, 1825-1830 (2007). (Pubitemid 350002185)
4. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005). (Pubitemid 43093963)
5. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin Cell Biol. 21, 154-165 (2009).
6. Cao Y, Cao R, Hedlund EM. Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J. Mol. Med. 86, 785-789 (2008).
7. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 16, 159-178 (2005). (Pubitemid 40616114)
8. Blumenschein GR Jr, Gatzemeier U, Fossella F et al. Phase II, multicenter, uncontrolled trial of single-Agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J. Clin. Oncol. 27, 4274-4280 (2009).
9. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004). (Pubitemid 39331023)
10. Nexavar® (sorafenib) tablets, oral, package insert. Bayer Health-Care Pharmaceuticals, Inc., Wayne, NJ, USA.
11. Carter C, Chen C, Brink C et al. Sorafenib is efficacious and tolerated in combination with cytostatic agents in preclinical models of human non-small cell lung carcinoma. Cancer Chemother. Pharmacol. 59, 183-195 (2007). (Pubitemid 44885148)
12. Minami H, Kawada K, Ebi H et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci. 99, 1492-1498 (2008). (Pubitemid 351761743)
13. Schiller JH, Lee JW, Hanna NH, Traynor AM, Carbone DP. A randomized discontinuation Phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501. J. Clin. Oncol. 26 (2008) (Abstract 8014).
14. Schiller JH, Flaherty KT, Redlinger M et al. Sorafenib combined with carboplatin/ paclitaxel for advanced non-small cell lung cancer: A Phase I subset analysis. J. Clin. Oncol. 24, Abstract 7194 (2006).
15. Scagliotti G, Novello S, Von PJ, Reck M et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1835-1842 (2010).
16. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J. Clin. Oncol. 23, 2544-2555 (2005).
17. Tonra JR, Deevi DS, Corcoran E et al. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 12, 2197-2207 (2006).
18. Lind JS, Dingemans AM, Groen HJ et al. A multicenter, Phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin. Cancer Res. 16, 3078-3087 (2010).
19. Herbst RS, Blumenschein GR Jr, Kim ES et al. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker- Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J. Clin. Oncol. 28, Abstract 7609 (2010).
20. Cabebe E, Wakelee H. Role of anti-Angiogenesis agents in treating NSCLC: Focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr. Treat. Options Oncol. 8, 15-27 (2007).
21. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2, 471-478 (2003).
22. Novello S, Scagliotti GV, Rosell R et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br. J. Cancer 101, 1543-1548 (2009).
23. Socinski MA, Novello S, Brahmer JR et al. Multicenter, Phase II trial of sunitinib in previously treated, advanced nonsmall-cell lung cancer. J. Clin. Oncol. 26, 650-656 (2008). (Pubitemid 351264362)
24. Reck M, Frickhofen N, Cedres S et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A Phase I dose-escalation study. Lung Cancer 70(2), 180-187 (2010).
25. Robert F, Sandler A, Schiller JH et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: A Phase I dose-escalation study. Cancer Chemother. Pharmacol. 66(4), 669-680 (2010).
26. Hennequin LF, Stokes ES, Thomas AP et al. Novel 4-Anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 45, 1300-1312 (2002). (Pubitemid 34263566)
27. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645-4655 (2002).
28. Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann. Oncol. 16, 1391-1397 (2005). (Pubitemid 41158486)
29. Natale RB, Bodkin D, Govindan R et al. Vandetanib versus gefitinib in patients with advanced non-small cell lung cancer: Results from a two-part, double-blind, randomized Phase II trial. J. Clin. Oncol. 27, 2523-2529 (2009).
30. Heymach JV, Johnson BE, Prager D et al. Randomized, placebo-controlled Phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J. Clin. Oncol. 25, 4270-4277 (2007). (Pubitemid 47548567)
31. Heymach V, Paz-Ares L, De Braud F et al. Randomized Phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J. Clin. Oncol. 26, 5407-5415 (2008).
32. Herbst RS, Sun Y, Eberhardt WE et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, Phase 3 trial. Lancet Oncol. 11(7), 619-626 (2010).
33. Johnson E, Ryan AJ, Heymach J et al. Tumor biomarker analyses from the Phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. J. Clin. Oncol. 28, Abstract 7516 (2010).
34. De Boer R, Arrieta O, Yang CH et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind Phase III trial (ZEAL). J. Clin. Oncol. 1067-1074 (2011).
35. Natale RB, Thongprasert S, Greco FA et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind Phase III trial (ZEST). J. Clin. Oncol. 27, Abstract 8009 (2009).
36. Lee J, Hirsch V, Park K et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind Phase III trial (ZEPHYR). J. Clin. Oncol. 28, Abstract 7525 (2010).
37. Hilberg F, Roth GJ, Krssak M et al. BIBF1120: Triple angiokinase inhibitor with sustained receptor blockade and good anti-Tumor efficacy. Cancer Res. 68(12), 4774-4782 (2008).
38. Hilberg F, Brandstetter I, Roth GJ. In vitro and in vivo efficacy of BIBF 1120, a small molecule triple angiokinase inhibitor, in combination with taxanes. Proceedings AACR-NCI-EORTC. Int. Conf. Mol. Targets Cancer Ther. 59, A19 (2005).
39. Stopfer P, Roth W, Mross KB et al. Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) inadvanced cancer patients. Eur. J. Cancer Suppl. 4(12), 26 (2006).
40. Lee CP, Taylor NJ, Attard G et al. A Phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). J. Clin. Oncol. 24(18S), 3015 (2006).
41. Kaneda H, Okamoto I, Satoh T et al. Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumours (and presentation). Eur. J. Cancer Suppl. 7(2), Abstract 1243 (2009).
42. Camidge DR, Conkling P, Stephenson J, Shapiro D. A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC). J. Thoracic Oncol. 2(8), S730 (2007).
43. Hanna N, Ellis P, Stopfer P et al. A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer. J. Thoracic Oncol. 2(8), S717 (2007).
44. Von Pawel J, Kaiser R, Eschbach C et al. Efficacy, safety and pharmacokinetic (PK) results of a Phase II study with the triple angiokinase inhibitor BIBF 1120 in patients suffering from advanced non small cell lung cancer (NSCLC). J. Thoracic Oncol. 3(4), S61 (2008).
45. Reck M, Kaiser R, Eschbach C et al. A Phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann. Oncol. 22(6), 1374-1381 (2011).
46. Heckman CA, Holopainen T, Wirzenius M et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 68, 4754-4762 (2008).
47. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65, 4389-4400 (2005). (Pubitemid 40775678)
48. Laurie SA, Gauthier I, Arnold A et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: The National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 26, 1871-1878 (2008).
49. Goss G, Shepherd FA, Laurie S et al. A Phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer 45, 782-788 (2009).
50. Goss GD, Arnold A, Shepherd FA et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC Clinical Trials Group BR24 study. J. Clin. Oncol. 28, 49-55 (2010).
51. Gadgeel SM, Wozniak A, Edelman MJ et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J. Clin. Oncol. 27 (2009) (Abstract e19007).
52. Dy GK, Mandrekar SJ, Nelson GD et al. A randomized Phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. (Meeting Abstracts) 28, 7603 (2010).
53. Choueiri TK. Axitinib, a novel anti-Angiogenic drug with promising activity in various solid tumors. Curr. Opin Investig. Drugs 9, 658-671 (2008). (Pubitemid 351777169)
54. Kelly RJ, Rixe O. Axitinib (AG-013736). Recent Results Cancer Res. 184, 33-44 (2010).
55. Martin LP, Kozloff MF, Krzakowski M et al. Axitinib (AG-013736; AG) combined with chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) and other solid tumors. J. Clin. Oncol. 27, S15 Abstract 3559 (2009).
56. Rugo HS, Herbst RS, Liu G et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J. Clin. Oncol. 23, 5474-5483 (2005).
57. Schiller JH, Larson T, Ou SH et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: Results from a Phase II study. J. Clin. Oncol. 27, 3836-3841 (2009).
58. Schutz FA, Choueiri TK, Sternberg CN. Pazopanib: Clinical development of a potent anti-Angiogenic drug. Crit. Rev. Oncol. Hematol. (2010).
59. Hurwitz HI, Dowlati A, Saini S et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15, 4220-4227 (2009).
60. Altorki N, Guarino M, Lee P et al. Preoperative treatment with pazopanib (GW786034) a multikinase angiogenesis inhibitor in early stage non-small cell lung cancer (NSCLC): A proof-of-concept Phase II study. J. Clin. Oncol. 26, Abstract 7557 (2008).
61. Polverino A, Coxon A, Starnes C et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 66, 8715-8721 (2006). (Pubitemid 44449188)
62. Crawford J, Burris H, Stephenson J Jr et al. Safety and pharmacokinetics (PK) of AMG 706 in combination with panitumumab and gemcitabine-cisplatin in patients (pts) with advanced cancer. J. Clin. Oncol. 25, Abstract 14057 (2007).
63. Blumenschein GR Jr, Reckamp K, Stephenson GJ et al. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin. Cancer Res. 16, 279-290 (2010).
64. Blumenschein GR, Kabbinavar FF, Menon H et al. Randomized, open-label Phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). J. Clin. Oncol. 28, Abstract 7528 (2010).
65. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab - An Eastern Cooperative Oncology Group Study. Clin. Cancer Res. 14, 1407-1412 (2008). (Pubitemid 351413922)
66. Witkowska AM, Borawska MH. Soluble intercellular adhesion molecule-1 (sICAM-1): An overview. Eur. Cytokine Netw. 15, 91-98 (2004). (Pubitemid 38980081)
67. Hanrahan EO, Ryan AJ, Mann H et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin. Cancer Res. 15, 3600-3609 (2009).
68. Hanrahan EO, Lin HY, Kim ES et al. Distinct patterns of cytokine and angiogenic factor modulationin and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 28, 193-201 (2010).
69. Hanrahan EO, Ryan AJ, Mann H et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin. Cancer Res. 15, 3600-3609 (2009).
70. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23, 5892-5899 (2005).
71. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A Phase III trial-INTACT 2. J. Clin. Oncol. 22, 785-794 (2004). (Pubitemid 41103589)
72. Gatzemeier U, Pluzanska A, Szczesna A et al. for the TALENT study investigators. Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 22, 7010 (2004).
73. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A Phase III trial - INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004). (Pubitemid 41103588)
74. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in nonsmall-cell lung cancer. Clin. Lung Cancer 7, 385-388 (2006). (Pubitemid 44043547)
75. Vroling L, Lind JS, De Haas RR et al. CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. Br. J. Cancer 102, 268-275 (2010).
76. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46, 293-298 (2004). (Pubitemid 39487303)
77. Kim ES, Herbst RS, Lee JJ et al. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): Personalizing therapy for lung cancer. Presented at: 101st Annual Meeting of the American Association for Cancer Research. 2010.